<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03701581</url>
  </required_header>
  <id_info>
    <org_study_id>57379</org_study_id>
    <nct_id>NCT03701581</nct_id>
  </id_info>
  <brief_title>4-aminopyridine Treatment for Nerve Injury</brief_title>
  <official_title>4-aminopyridine Treatment for Nerve Injury Resulting From Radical Retro-Pubic Prostatectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Rochester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Milton S. Hershey Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Rochester</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the role of 4-aminopyridine (4-AP) on the course of recovery after peripheral&#xD;
      nerve traction and/or crush injury. This study aims to test the hypothesis that&#xD;
      4-aminopyridine speeds the often slow and unpredictable recovery after peripheral nerve&#xD;
      traction and/or crush injuries.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the role of 4-AP on the recovery of nerve function we will be giving patients&#xD;
      with prostate cancer who are undergoing robot assisted radical prostatectomy (RP) either 4-AP&#xD;
      or placebo in the perioperative period. This population of patients was selected as nerve&#xD;
      crush injury during RP is thought to contribute to erectile dysfunction and urinary&#xD;
      continence post operatively.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 5, 2021</start_date>
  <completion_date type="Anticipated">August 5, 2025</completion_date>
  <primary_completion_date type="Anticipated">August 5, 2023</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized placebo-controlled trial of 4AP vs placebo for nerve injury</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Michigan Incontinence Sympton Index (M-ISI) (change over time)</measure>
    <time_frame>Pre-operative visit, and every seven days (starting after surgery, i.e., 7 days post-op) for 6 months (up to 25 times).</time_frame>
    <description>Incontinence measurement (change over time)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>International Index of Erectile Function (IIEF) (change over time)</measure>
    <time_frame>Pre-operative visit, and every seven days (starting after surgery, i.e., 7 days post-op) for 6 months (up to 25 times).</time_frame>
    <description>Erectile function measurement tool. (change over time)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>University of Rochester Placebo vs. Active Drug Questionnaire</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Specific questions regarding patient blinding</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Drug Diary</measure>
    <time_frame>Daily for 90 days.</time_frame>
    <description>Subjects will record the time each day that they take the study drug/ placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>University of Rochester Attempted Sexual Activity Questionnaire</measure>
    <time_frame>Pre-operative visit, and every seven days (starting after surgery, i.e., 7 days post-op) for 6 months (up to 25 times).</time_frame>
    <description>Sexual activity assessment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Nerve Injury</condition>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Group A: Investigational Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4-Aminopyridine (FDA-approved drug)&#xD;
Subjects will not take more than 2 tablets in a 24-hour period&#xD;
Subjects will take the tablets whole. They will not break, crush, chew, or dissolve tablets before swallowing.&#xD;
The subjects will be told that the medication is released slowly over time and if the tablet is broken, the medicine may be released too fast which can raise the chance of having a seizure.&#xD;
Study drug can be taken with or without food.&#xD;
If a dose is missed they should not make up the missed dose. They will be told not to take two doses at the same time but to take the next dose at the regular scheduled time.&#xD;
Subjects will be reminded not to take study drug together with other aminopyridine medications, including compounded 4-AP (sometimes called 4-aminopyridine or fampridine).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive an oral dose of placebo treatment the day after surgery, continuing daily for 3 months (90 days) following the same administration instructions as the investigational treatment. The placebo tablets will be manufactured by The University of Iowa Pharmaceuticals, 115 South Grand Avenue G-20, Iowa City, IA 52242. The Investigational Drug Service at the University of Rochester will manage the placebos.&#xD;
Placebo composition will include:&#xD;
97% Microcrystalline Cellulose, NF (Avicel Ph 102) 2% Sodium Starch Glycolate, NF&#xD;
1% Magnesium Stearate, NF&#xD;
The placebo will be covered in White Opadry, formulation OY-S-9603 and tooled to look similar to the investigational treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>4-Aminopyridine</intervention_name>
    <description>FDA-approved tablets.</description>
    <arm_group_label>Group A: Investigational Treatment</arm_group_label>
    <other_name>4-AP</other_name>
    <other_name>Fampridine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be tooled to look similar to the study drug.</description>
    <arm_group_label>Group B: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Male patients with organ-confined, non-metastatic prostate cancer (stages cT1c-T2c),&#xD;
             planning to undergo Robotic-Assisted Laparoscopic Bilateral Nerve Sparing Radical&#xD;
             Prostatectomy (NSRP)&#xD;
&#xD;
          -  Prostate-Specific Antigen (PSA) levels less than 15 ng/ml (within the last 12 months),&#xD;
             with biopsy-proven prostate cancer, for whom postoperative adjuvant therapy (e.g.&#xD;
             radiation or androgen deprivation therapy) is not expected to be needed&#xD;
&#xD;
          -  Ages 45-75&#xD;
&#xD;
          -  An Abridged International Index of Erectile Function-Erectile Function (IIEF-5) score&#xD;
             of greater than or equal to 17 at time of screening&#xD;
&#xD;
          -  Has experienced at least 6 months of regular sexual activity and sexual activity&#xD;
             during the 12 weeks prior to prostate biopsy or surgery&#xD;
&#xD;
          -  Willingness to abstain from treatments for Erectile Dysfunction until 3 months after&#xD;
             surgery&#xD;
&#xD;
          -  Willingness to participate and able to provide informed consent&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Planned adjuvant therapy after NSRP based on specimen pathology and stage of prostate&#xD;
             cancer (stage T3 or greater), positive lymph nodes or positive surgical margins&#xD;
&#xD;
          -  Neo-adjuvant therapy prior to NSRP&#xD;
&#xD;
          -  History of recurrent prostate cancer&#xD;
&#xD;
          -  History of seizures, multiple sclerosis, stroke or any other diagnosed neurological&#xD;
             disorder&#xD;
&#xD;
          -  History of non-organ confined or metastatic prostate cancer (clinical Stages T3 or&#xD;
             greater)&#xD;
&#xD;
          -  History of known hypersensitivity to 4AP&#xD;
&#xD;
          -  Patients with history of penile surgery other than circumcision or endoscopic urethral&#xD;
             stricture surgery&#xD;
&#xD;
          -  Renal impairment based on calculated GFR (GFR&lt;60 mL/min)&#xD;
&#xD;
          -  Use of any other aminopyridine medications for any other indication&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Restricted to male subjects due to the inclusion criteria of prostate cancer.</gender_description>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmed Ghazi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Rochester, Department of Urology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Elfar, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Rochester, and The Pennsylvania State University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elizabeth Galgocy</last_name>
    <phone>(717) 531-8521</phone>
    <email>egalgocy@pennstatehealth.psu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ananya Das</last_name>
    <phone>7175314686</phone>
    <email>adas1@pennstatehealth.psu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Rochester Department of Urology</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ahmed Ghazi, MD</last_name>
      <phone>585-402-4868</phone>
      <email>ahmed_ghazi@urmc.rochester.edu</email>
    </contact>
    <contact_backup>
      <last_name>Thomas L Osinski, MD</last_name>
      <phone>585-705-0247</phone>
      <email>thomas_osinski@urmc.rochester.edu</email>
    </contact_backup>
    <investigator>
      <last_name>John Elfar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ahmed Ghazi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Edward Messing, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mark Noble, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas L Osinski, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ahmed Ghazi, MD</last_name>
      <phone>585-275-2838</phone>
      <email>ahmed_ghazi@urmc.rochester.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>October 25, 2017</study_first_submitted>
  <study_first_submitted_qc>October 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 10, 2018</study_first_posted>
  <last_update_submitted>July 14, 2021</last_update_submitted>
  <last_update_submitted_qc>July 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Rochester</investigator_affiliation>
    <investigator_full_name>John Elfar</investigator_full_name>
    <investigator_title>Adjunct Associate Professor, Department of Orthopaedics (URMC) and Vice Chairman, Department of Orthopaedics and Rehabilitation (Penn State)</investigator_title>
  </responsible_party>
  <keyword>prostatectomy</keyword>
  <keyword>erectile dysfunction</keyword>
  <keyword>prostate cancer</keyword>
  <keyword>nerve injury</keyword>
  <keyword>incontinence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>4-Aminopyridine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>At the conclusion of the study, de-identified patient outcomes will be provided with publication of results. This includes outcomes data as listed in the primary and secondary outcomes sections.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>For five years post study conclusion and publication.</ipd_time_frame>
    <ipd_access_criteria>Per the accepting journal.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

